View Older Stories View More Recent Stories
-
Morgan Stanley: China healthcare sector dips 1.3% amid licensing scrutiny
-
Pfizer's LORBRENA shows 55% seven-year survival without progression
-
UBS Reiterates Neutral Rating on Pfizer (PFE)
-
Arvinas Inc. (ARVN) PT Raised to $16 at BofA Securities
-
European Commission approves Pfizer's HYMPAVZI for hemophilia with inhibitors
-
FDA Commissioner Marty Makary to step down - Politico
-
Arvinas and Pfizer sell VEPPANU rights to Rigel for $85 million upfront
-
MBX Biosciences (MBX) PT Raised to $86 at Citizens on 'Good' MBX 4291 Update
-
HHS downplays Hantavirus risk amid repatriation efforts
-
Health officials explore restrictions on certain SSRI antidepressants - Reuters
-
Novo Nordisk Eyes Large-Scale M&A Following Pfizer's Metsera Win - Semafor
-
Pfizer (PFE) PT Raised to $27 at BofA Securities
-
Pfizer Reviewing New Molecule It Designed Using AI - CEO
-
Pfizer beats first quarter estimates on strong product growth
-
Pfizer (PFE) Tops Q1 EPS by 3c, Beats on Revenue; Offers FY26 EPS Guidance
-
Pfizer (PFE) call put ratio 4.7 calls to 1 put quarter results
-
Pfizer (PFE) calls more active than puts into quarter results
-
Pfizer (PFE) call put ratio 2.9 calls to 1 put with a focus on May 8 weekly 27 calls into quarter results
-
Pfizer's ELREXFIO meets primary endpoint in multiple myeloma trial
-
Raymond James on BridgeBio Pharma (BBIO): 'We expect continued strong commercial momentum for Attruby'
-
Barclays on BridgeBio Pharma (BBIO): 'We see buying opportunity on weakness, reiterate top idea'
-
TD Cowen on BridgeBio Pharma (BBIO): 'A key overhang is removed now'
-
RBC Capital on BridgeBio Pharma (BBIO): 'we remain buyers'
-
Mizuho on BridgeBio Pharma (BBIO): 'Not Best Case but Still Good Outcome Relative to Street'
-
Morgan Stanley on Pfizer (PFE): 'we believe generic versions of Vyndaqel could still represent a potential headwind to the franchise'
-
Pfizer extends VYNDAMAX patent protection to 2031 through settlements
-
Mizuho: 'BBIO could potentially trade in the $90-110+ range today / near-term'
-
RBC on Pfizer (PFE): 'Litigation overhang cleared'
-
Barclays: 'We think dropping the question of '441 validity from the case is a major development'
-
Bristol Myers Squibb and Pfizer partner with Mark Cuban's Cost Plus Drugs
-
CICC Starts Pfizer (PFE) at Outperform
-
Pfizer (PFE) PT Raised to $27 at UBS
-
Guggenheim Reiterates Buy Rating on Pfizer (PFE)
-
Pfizer (PFE) PT Lowered to $26 at BofA Securities
-
RBC Capital Reiterates Underperform Rating on Pfizer (PFE)
-
Leerink Partners on Pfizer (PFE): 'positive ruling today should drive additional Comirnaty OUS sales'
-
Pfizer (PFE) to shutter South S.F. research site, end Bay Area presence - Bloomberg
-
Wolfe: 'We're observing some reports of GLP-1 users refreshing their wardrobes as weight loss progresses'
-
Pfizer (PFE) PT Raised to $36 at Guggenheim
-
Pfizer advises shareholders to reject Tutanota mini-tender offer
-
Pfizer's TALZENNA combination shows progress against prostate cancer
-
Morgan Stanley on Pfizer (PFE): Atirmo Ph2 data an 'incremental positive'
-
Stocks expected to have increasing option volume: LMND MRNA PFE BNTX NVAX AZN BMY LLY GSK JNJ MRK NVS MRK SNY
-
US Judge blocks Trump Admin cuts to number of routinely recommended vaccines for children - Reuters
-
BMO Capital Reiterates Outperform Rating on Pfizer (PFE) following Ph2 data
-
FDA: 'The agency today is withdrawing final guidance titled “Scientific Considerations in Demonstrating Biosimilarity to a Reference Product'
-
Argus Upgrades Pfizer (PFE) to Buy
-
PADCEV plus Keytruda reduces bladder cancer recurrence risk by 47%
-
RBC Capital Starts Pfizer (PFE) at Underperform
-
FDA approves Pfizer's BRAFTOVI for colorectal cancer treatment

